20xx年醫(yī)學(xué)專題—antianginal-drugs(抗心絞痛藥)(編輯修改稿)
2024-10-31 14:05 本頁面
【文章內(nèi)容簡介】 rse effects,2. Antianginal drugs,第十六頁，共三十一頁。,第十七頁，共三十一頁。,2.2 ? receptor blockers A. Pharmacological action Reducing oxygen demand: heart rate and contractility ? Increasing oxygen supply: diastolic period ?: perfusion time ? vascular tone in normal regions ?: blood flow in ischemic regions ? Others: Improving myocardial metabolism Inhibiting coagulation of platelets,2. Antianginal drugs,,第十八頁，共三十一頁。,B. Clinical uses stable and unstable pectoris, especially associated with hypertension or arrhythmias, even with myocardial infarction。 but not used for variant angina pectoris C. Notes Dose individualization: starting from small dose Withdraw gradually and slowly: symptom rebound Combination with nitroglycerin,2. Antianginal drugs,第十九頁，共三十一頁。,2.3 Calcium channel blockers,2. Antianginal drugs,第二十頁，共三十一頁。,2.3 Calcium channel blockers A. Pharmacological actions Reducing myocardial oxygen remand: heart loads ?: nifedipine heart rate and contractility ?: verapamil and diltiazem Increasing myocardial blood supply Protecting ischemic myocardial cells Inhibiting coagulation of platelets,2. Antianginal drugs,第二十一頁，共三十一頁。,Actions of calcium channel blockers,第二十二頁，共三十一頁。,B. Clinical uses stable and variant type: nifedipine, verapamil, diltiazem unstable type: verapamil, diltiazem,2. Antianginal drugs,Actions of DHP (like nifedipine) are similar to those of nitroglycerin Actions of verapamil and diltiazem are similar to those of ? blockers,第二十三頁，共三十一頁。,2.4 Other drugs ACEIs 〔血管緊張(jǐnzhāng)素轉(zhuǎn)化酶抑制藥〕
電大資料相關(guān)推薦
鄂ICP備17016276號-1